Literature DB >> 15209520

Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification, site-directed mutagenesis, and pre-steady state and steady state kinetic studies.

Haiqing Wang1, Gregory M Vath, Kara J Gleason, Patrick E Hanna, Carston R Wagner.   

Abstract

Arylamine N-acetyltransferases (NATs) catalyze an acetyl group transfer from acetyl coenzyme A (AcCoA) to arylamines, hydrazines, and their N-hydroxylated arylamine metabolites. The recently determined three-dimensional structures of prokaryotic NATs have revealed a cysteine protease-like Cys-His-Asp catalytic triad, which resides in a deep and hydrophobic pocket. This catalytic triad is strictly conserved across all known NATs, including hamster NAT2 (Cys-68, His-107, and Asp-122). Treatment of NAT2 with either iodoacetamide (IAM) or bromoacetamide (BAM) at neutral pH rapidly inactivated the enzyme with second-order rate constants of 802.7 +/- 4.0 and 426.9 +/- 21.0 M(-1) s(-1), respectively. MALDI-TOF and ESI mass spectral analysis established that Cys-68 is the only site of alkylation by IAM. Unlike the case for cysteine proteases, no significant inactivation was observed with either iodoacetic acid (IAA) or bromoacetic acid (BAA). Pre-steady state and steady state kinetic analysis with p-nitrophenyl acetate (PNPA) and NAT2 revealed a single-exponential curve for the acetylation step with a second-order rate constant of (1.4 +/- 0.05) x 10(5) M(-1) s(-1), followed by a slow linear rate of (7.85 +/- 0.65) x 10(-3) s(-1) for the deacetylation step. Studies of the pH dependence of the rate of inactivation with IAM and the rate of acetylation with PNPA revealed similar pK(a)(1) values of 5.23 +/- 0.09 and 5.16 +/- 0.04, respectively, and pK(a)(2) values of 6.95 +/- 0.27 and 6.79 +/- 0.25, respectively. Both rates reached their maximum values at pH 6.4 and decreased by only 30% at pH 9.0. Kinetic studies in the presence of D(2)O revealed a large inverse solvent isotope effect on both inactivation and acetylation of NAT2 [k(H)(inact)/k(D)(inact) = 0.65 +/- 0.02 and (k(2)/K(m)(acetyl))(H)/(k(2)/K(m)(acetyl))(D) = 0.60 +/- 0.03], which were found to be identical to the fractionation factors (Phi) derived from proton inventory studies of the rate of acetylation at pL 6.4 and 8.0. Substitution of the catalytic triad Asp-122 with either alanine or asparagine resulted in the complete loss of protein structural integrity and catalytic activity. From these results, it can be concluded that the catalytic mechanism of NAT2 depends on the formation of a thiolate-imidazolium ion pair (Cys-S(-)-His-ImH(+)). However, in contrast to the case with cysteine proteases, a pH-dependent protein conformational change is likely responsible for the second pK(a), and not deprotonation of the thiolate-imidazolium ion. In addition, substitutions of the triad aspartate are not tolerated. The enzyme appears, therefore, to be engineered to rapidly form a stable acetylated species poised to react with an arylamine substrate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15209520     DOI: 10.1021/bi0497244

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  23 in total

1.  Arylamine N-acetyltransferases: a structural perspective. Comments regarding the BJP paper by Zhou et al., 2013.

Authors:  Ximing Xu; Xavier Kubiak; Jean-Marie Dupret; Fernando Rodrigues-Lima
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

2.  Comparison of the Arylamine N-acetyltransferase from Mycobacterium marinum and Mycobacterium tuberculosis.

Authors:  Elizabeth Fullam; Akane Kawamura; Helen Wilkinson; Areej Abuhammad; Isaac Westwood; Edith Sim
Journal:  Protein J       Date:  2009-08       Impact factor: 2.371

3.  Kinetic and chemical mechanism of arylamine N-acetyltransferase from Mycobacterium tuberculosis.

Authors:  Alison L Sikora; Brenda A Frankel; John S Blanchard
Journal:  Biochemistry       Date:  2008-09-17       Impact factor: 3.162

Review 4.  Arylamine N-acetyltransferases: a structural perspective.

Authors:  Xiaotong Zhou; Zhiguo Ma; Dong Dong; Baojian Wu
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

5.  Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1.

Authors:  Haiqing Wang; Gregory M Vath; Akane Kawamura; Caleb A Bates; Edith Sim; Patrick E Hanna; Carston R Wagner
Journal:  Protein J       Date:  2005-02       Impact factor: 2.371

6.  Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines.

Authors:  James Sandy; Adeel Mushtaq; Simon J Holton; Pamela Schartau; Martin E M Noble; Edith Sim
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

7.  Structural and biochemical characterization of an active arylamine N-acetyltransferase possessing a non-canonical Cys-His-Glu catalytic triad.

Authors:  Xavier Kubiak; Inès Li de la Sierra-Gallay; Alain F Chaffotte; Benjamin Pluvinage; Patrick Weber; Ahmed Haouz; Jean-Marie Dupret; Fernando Rodrigues-Lima
Journal:  J Biol Chem       Date:  2013-06-16       Impact factor: 5.157

8.  Probing the catalytic potential of the hamster arylamine N-acetyltransferase 2 catalytic triad by site-directed mutagenesis of the proximal conserved residue, Tyr190.

Authors:  Xin Zhou; Naixia Zhang; Li Liu; Kylie J Walters; Patrick E Hanna; Carston R Wagner
Journal:  FEBS J       Date:  2009-10-23       Impact factor: 5.542

Review 9.  Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.

Authors:  Jason M Walraven; Yu Zang; John O Trent; David W Hein
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

Review 10.  Arylamine N-acetyltransferases in mycobacteria.

Authors:  Edith Sim; James Sandy; Dimitrios Evangelopoulos; Elizabeth Fullam; Sanjib Bhakta; Isaac Westwood; Anna Krylova; Nathan Lack; Martin Noble
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.